{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:40:47Z","timestamp":1792057247558,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00228-021-03253-3","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T09:04:06Z","timestamp":1642755846000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9103","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"10","key":"3253_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L et al (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131(10):1094\u20131105","journal-title":"Blood"},{"issue":"3","key":"3253_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Stock W, Zeidan A et al (2020) Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv 4(3):449\u2013457","journal-title":"Blood Adv"},{"issue":"19","key":"3253_CR3","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C et al (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood 137(19):2634\u20132645","journal-title":"Blood"},{"issue":"23","key":"3253_CR4","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J et al (2019) A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res 25(23):6986\u20136994","journal-title":"Clin Cancer Res"},{"key":"3253_CR5","unstructured":"American Cancer Society (2021) Types of B-cell Lymphoma. Available at: https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html. Accessed June 2021"},{"key":"3253_CR6","doi-asserted-by":"crossref","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116:2040\u20132045","DOI":"10.1182\/blood-2010-03-276246"},{"key":"3253_CR7","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U et al (2018-2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood 131(5):587\u2013588].\u00a0Blood 130(16):1800\u20131808","DOI":"10.1182\/blood-2017-03-769620"},{"issue":"7","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","volume":"21","author":"JA Hartley","year":"2021","unstructured":"Hartley JA (2021) Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther 21(7):931\u2013943","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","volume":"14","author":"Y Chu","year":"2021","unstructured":"Chu Y, Zhou X, Wang X (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol 14(1):88","journal-title":"J Hematol Oncol"},{"key":"3253_CR10","unstructured":"ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma. https:\/\/ir.adctherapeutics.com\/press-releases\/press-release-details\/2020\/ADC-Therapeutics-Submits-Biologics-License-Application-to-the-U.S.-Food-and-Drug-Administration-for-Loncastuximab-Tesirine-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma\/default.aspx"},{"key":"3253_CR11","unstructured":"FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-loncastuximab-tesirine-lpyl-large-b-cell-lymphoma"},{"issue":"6","key":"3253_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790\u2013800","journal-title":"Lancet Oncol"},{"issue":"6","key":"3253_CR13","first-page":"414","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) FDA approves ADC Therapeutics\u2019 loncastuximab tesirine, ushering in a new cytotoxic payload. Nat Rev Drug Discov 20(6):414","journal-title":"Nat Rev Drug Discov"},{"key":"3253_CR14","unstructured":"Zynlonta\u2122 Press Releases. ADC Therapeutics SA. https:\/\/ir.adctherapeutics.com\/press-releases\/default.aspx"},{"key":"3253_CR15","unstructured":"Zynlonta\u2122 Prescribing Information. ADC Therapeutics SA. https:\/\/www.adctherapeutics.com\/wp-content\/uploads\/2021\/04\/pi.pdf"},{"key":"3253_CR16","doi-asserted-by":"crossref","unstructured":"Tarantelli C et al (2019) \"The antibody-drug conjugate (ADC) loncastuximab tesirine (ADCT-402) targeting CD19 shows strong in vitro anti-lymphoma activity both as single agents and in combination.\" Hematological Oncology 37: 129\u2013130.","DOI":"10.1002\/hon.90_2629"},{"key":"3253_CR17","doi-asserted-by":"crossref","unstructured":"Depaus J et al (2021) \"Clinical activity of loncastuximab tesirine plus ibrutinib in non\u2010hodgkin lymphoma: Updated lotis 3 phase 1 results.\"\u00a0Hematologi Oncol\u00a039","DOI":"10.1002\/hon.150_2880"},{"key":"3253_CR18","unstructured":"Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03684694"},{"key":"3253_CR19","doi-asserted-by":"crossref","unstructured":"Zinzani, PL et al (2021) \"Lotis 2 follow-up analysis: Updated results from a phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large b-cell lymphoma.\"\u00a0Hematol Oncol\u00a039 (2021)","DOI":"10.1002\/hon.89_2880"},{"key":"3253_CR20","doi-asserted-by":"crossref","unstructured":"Caimi, Paolo F et al (2020) \"Efficacy and safety of loncastuximab tesirine (ADCT-402) in relapsed\/refractory diffuse large B-cell lymphoma.\"\u00a0Blood\u00a0136(Suppl 1):35\u201337","DOI":"10.1182\/blood-2020-137524"},{"key":"3253_CR21","doi-asserted-by":"crossref","unstructured":"Thapa B, Caimi PF, Ardeshna KM et al (2020) CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy [published correction appears in Blood Adv\u00a04(19):4606].\u00a0Blood Adv 4(16):3850\u20133852","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"3253_CR22","unstructured":"Spira A, Zhou X, Chen L et al (2021) Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [published online ahead of print, 2021 Sep 22].\u00a0Clin Lymphoma Myeloma Leuk\u00a0S2152\u20132650(21)02031\u20130"},{"key":"3253_CR23","doi-asserted-by":"crossref","unstructured":"Alderuccio JP et al (2021) \"ABCL\u2013396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R\/R DLBCL in the LOTIS Clinical Trial Program.\"\u00a0Clin Lymphoma Myeloma Leuk 21:S397\u2013S398","DOI":"10.1016\/S2152-2650(21)01899-1"},{"key":"3253_CR24","doi-asserted-by":"crossref","unstructured":"Solh Melhem et al (2021) \"ABCL\u2013362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R\/R DLBCL in a Pooled Safety Analysis.\"\u00a0Clin Lymphoma Myeloma Leuk 21: S394\u2013S395","DOI":"10.1016\/S2152-2650(21)01894-2"},{"issue":"5","key":"3253_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamadermatol.2020.0208","volume":"156","author":"EP Sorensen","year":"2020","unstructured":"Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA (2020) Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies. JAMA Dermatol 156(5):601\u2013603","journal-title":"JAMA Dermatol"},{"key":"3253_CR26","unstructured":"Drugs and Lactation Database (LactMed) (2021). Bethesda (MD): National Library of Medicine (US); 2006\u2013. Loncastuximab Tesirine"},{"key":"3253_CR27","unstructured":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384484"},{"key":"3253_CR28","unstructured":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04699461"},{"key":"3253_CR29","doi-asserted-by":"crossref","unstructured":"Liao L et al (2021) \"Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R\/R DLBCL) Who Have Received Two or More Prior Lines of Therapies.\"\u00a0Value in health. Vol. 24. STE 800, 230 Park Ave, New York, NY 10169 USA: Elsevier Science INC.,","DOI":"10.1016\/j.jval.2021.04.163"},{"key":"3253_CR30","unstructured":"Zynlonta Prices, Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/zynlonta"},{"key":"3253_CR31","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C et al (2019) \"Interim futility analysis of a phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large B-cell lymphoma.\"\u00a0Blood\u00a0134(Suppl 1): 757","DOI":"10.1182\/blood-2019-128401"},{"key":"3253_CR32","doi-asserted-by":"crossref","unstructured":"Hamadani M et al (2021) \"Phase 3 Randomized Study of Loncastuximab Tesirine plus Rituximab versus Immunochemotherapy in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-cell Lymphoma (DLBCL)\u2014LOTIS-5.\" TPS7574-TPS7574","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7574"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03253-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:06:35Z","timestamp":1649750795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03253-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03253-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"23 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Bo Xu declare that he has no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}